The Efficacy of Autologous Nebulized Platelet Rich Plasma (PRP) As an Early Adjuvant Therapeutic and Prognostic Treatment Modality in the Management of Inhalation Lung Injury

Salama, Shereine M; Kamel, Ibrahim H; Ghanim, Mohamed; Elsherif, Ahmad F

doi:10.21608/ejprs.2019.65115

Cited by 4 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A student's t-test and ANOVA were conducted, which showed the analysis of all measurements to be statistically significant (p-value was less than 0.05) [24]. Salama et al conducted a randomized controlled trial from 2015 to 2017 in order to assess the efficacy of nebulized autologous PRP in smoke inhalation patients [25]. The study included a total of 40: 20 in the study group and 20 acted as the control group [25].…”

Section: Review Resultsmentioning

confidence: 99%

Platelet-Rich Plasma Treatment for Chronic Respiratory Disease

Knight¹,

Kacker²

2023

Cureus

View full text Add to dashboard Cite

This study was conducted to test the hypothesis that platelet-rich plasma (PRP) therapy in chronic respiratory disease patients will cause lung regeneration, thereby slowing the progression of the disease.We performed a search to obtain pertinent articles on the following electronic databases: Google Scholar, PubMed, NCBI, Medscape, and clinicaltrials.gov. Keywords used during in search included "Platelet Rich Plasma" AND "Chronic Respiratory Disease" AND/OR "Chronic Obstructive Pulmonary Disease". A total of 15 articles were chosen for this paper, published from 2011 to 2021, and included case series, lab studies, animal studies, cohort studies, and clinical trials. All statistical data were considered significant if the pvalue was less than 5%, or 0.05.Our findings confirmed that PRP therapy successfully caused anti-inflammatory effects and acceleration of tissue regeneration, resulting in improved lung function. This, in turn, slowed the progression of the disease and led to an improved quality of life. Not all chronic respiratory disease patients present in the same manner, but the connecting link is the damaged tissue of the lungs, causing issues with the functionality of the lungs. By adjunctively treating patients with PRP, the high concentration of platelets and their secreted growth factors can help induce an acceleration of healing and regeneration of pulmonary tissue. This, in turn, can slow the progression of the disease, which could lower the overall mortality rate in chronic respiratory disease patients. More studies should be conducted on this topic, specifically large, double-blinded, randomized human trials with controls, to further assess the efficacy and beneficial effects of PRP treatment on the lungs.

show abstract

Section: Review Resultsmentioning

confidence: 99%

Platelet-Rich Plasma Treatment for Chronic Respiratory Disease

Knight¹,

Kacker²

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The authors concluded that PRP proved to be beneficial for lung inflammation and did not present biosecurity problems [ 72 ]. In addition to preclinical studies, a clinical study was conducted on burnt patients with airway disease [ 73 ]. This prospective study included 40 patients with 25–50% burns and inhalation lung injury.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with inhalation lung injury Aerosolized PRP Lower extubation time, hospital stay and mortality rate [73] The platelet action is key in respiratory infections, and it can both improve the disease and aggravate the patient's condition. Therefore, the balance in their functions is crucial in the evolution of the disease.…”

Section: Horses With Inflammatory Airway Disease Intrabronchial Instimentioning

confidence: 99%

Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale

Beitia¹,

Delgado²,

Sánchez³

et al. 2021

IJMS

View full text Add to dashboard Cite

One of the most severe effects of coronavirus disease 2019 (COVID-19) is lung disorders such as acute respiratory distress syndrome. In the absence of effective treatments, it is necessary to search for new therapies and therapeutic targets. Platelets play a fundamental role in respiratory disorders resulting from viral infections, being the first line of defense against viruses and essential in maintaining lung function. The direct application of platelet lysate (PL) obtained from the platelet-rich plasma of healthy donors could help in the improvement of the patient due its anti-inflammatory, immunomodulatory, antifibrotic, and repairing effects. This work evaluates PL nebulization by analyzing its levels of growth factors and its biological activity on lung fibroblast cell cultures, besides describing a scientific basis for its use in this kind of pathology. The data of the work suggest that the molecular levels and biological activity of the PL are maintained after nebulization. Airway administration would allow acting directly on the lung tissue modulating inflammation and stimulating reparative processes on key structures such as the alveolocapillary barrier, improving the disease and sequels. The protocol developed in this work is a first step for the study of nebulized PL both in animal experimentation and in clinical trials.

show abstract

“…Significant resolution compared to the previous examination results suggest a significant improvement in radiological images in group A after treatment secondary to the stem cell effect on reducing inflammation and stimulating the pulmonological healing process. This method is already being used as a treatment option for lung inflammation via nebulization, with an increase in the number of lungs' endothelial cells, accelerating airway healing and favorably altering the pathophysiological changes [23]. Few stem cell therapy trials have been reported, most of which were performed by intravenous injection techniques and not by nebulization.…”

Section: Discussionmentioning

confidence: 99%

Stem cell nebulization therapy for COVID-19 infection: radiological and clinical outcomes

Zambrano

Ahmed

Carmenate

et al. 2021

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background SARS-CoV-2 is a highly contagious virus that spread worldwide with a rapid increase in the number of deaths. In March 2020, the WHO declared SARS-CoV-2 a pandemic. The primary diagnostic test is reverse transcription-polymerase chain reaction, but chest X-ray and computed tomography have become the typical diagnostic tools used to detect abnormal lung changes. Within the framework of the SENTAD COVID Study clinical trial, an observational and analytical study was conducted, where the patients received nebulization therapy with the use of autologous stem cells (group A) compared to the control arm (group B). Both groups received the UAE SARS-CoV-2 standard management. Radiological images of each patient were collected within 24 h of inclusion in the trial and during follow-up. Herein, we describe and evaluate the radiological findings and outcomes. Results A total of 139 subjects were included in our analysis, 69 in group A and 70 in group B. The most common finding was ground glass opacifications, followed by patchy consolidations, with 20% normal radiological images scored 3 from admission until discharge (p < 0.0001). Our results suggest a significant improvement in radiological images after treatment secondary to the stem cell effect of reducing inflammation and stimulating the pneumological healing process. Conclusions The use of novel therapies, such as stem cells, shows efficacy not only in terms of the control of clinical and paraclinical signs but also in the radiological changes described in the disease. Trial registration Study evaluating the safety and efficacy of autologous non-hematopoietic peripheral blood stem cells in COVID-19. Trial registration number: NCT04473170. Date of registration: 16 July 20202. Retrospectively registered.

show abstract

The Efficacy of Autologous Nebulized Platelet Rich Plasma (PRP) As an Early Adjuvant Therapeutic and Prognostic Treatment Modality in the Management of Inhalation Lung Injury

Cited by 4 publications

References 10 publications

Platelet-Rich Plasma Treatment for Chronic Respiratory Disease

Platelet-Rich Plasma Treatment for Chronic Respiratory Disease

Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale

Stem cell nebulization therapy for COVID-19 infection: radiological and clinical outcomes

Contact Info

Product

Resources

About